Articles by Roy M Gulick, MD

Two-Year Safety and Virologic Efficacy of Maraviroc in Treatment-Experienced Patients With CCR5-Tropic HIV-1 Infection: 96-Week Combined Analysis of MOTIVATE 1 and 2

Hardy, W David; Gulick, Roy M; Mayer, Howard; More

JAIDS Journal of Acquired Immune Deficiency Syndromes. 55(5):558-564, December 15, 2010.

Three-Year Safety and Efficacy of Vicriviroc, a CCR5 Antagonist, in HIV-1–Infected Treatment-Experienced Patients

Wilkin, Timothy J; Su, Zhaohui; Krambrink, Amy; More

JAIDS Journal of Acquired Immune Deficiency Syndromes. 54(5):470-476, August 15, 2010.

Measurement of Naive CD4 Cells Reliably Predicts Potential for Immune Reconstitution in HIV

Schacker, Timothy W; Bosch, Ronald J; Bennett, Kara; More

JAIDS Journal of Acquired Immune Deficiency Syndromes. 54(1):59-62, May 1, 2010.

Racial Differences in Virologic Failure Associated With Adherence and Quality of Life on Efavirenz-Containing Regimens for Initial HIV Therapy: Results of ACTG A5095

Schackman, Bruce R; Ribaudo, Heather J; Krambrink, Amy; More

JAIDS Journal of Acquired Immune Deficiency Syndromes. 46(5):547-554, December 15, 2007.

Metabolic Effects of Protease Inhibitor-Sparing Antiretroviral Regimens Given as Initial Treatment of HIV-1 Infection (AIDS Clinical Trials Group Study A5095)

Shikuma, Cecilia M; Yang, Yang; Glesby, Marshall J; More

JAIDS Journal of Acquired Immune Deficiency Syndromes. 44(5):540-550, April 15, 2007.

Four Measures of Antiretroviral Medication Adherence and Virologic Response in AIDS Clinical Trials Group Study 359

Fletcher, Courtney V; Testa, Marcia A; Brundage, Richard C; More

JAIDS Journal of Acquired Immune Deficiency Syndromes. 40(3):301-306, November 1, 2005.